U.S. Markets closed

Xencor, Inc. (XNCR)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
23.78+0.78 (+3.39%)
At close: 4:00PM EDT
People also watch
MGNXXLRNFPRXVSAREPZM
Full screen
Previous Close23.00
Open23.28
Bid0.00 x
Ask0.00 x
Day's Range22.61 - 24.19
52 Week Range18.10 - 29.38
Volume211,814
Avg. Volume244,311
Market Cap1.11B
Beta1.91
PE Ratio (TTM)67.37
EPS (TTM)0.35
Earnings DateJul 31, 2017 - Aug 4, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.40
Trade prices are not sourced from all markets
  • Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : July 6, 2017
    Capital Cube16 days ago

    Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : July 6, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Xencor, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • PR Newswirelast month

    Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017

    MONROVIA, Calif., June 16, 2017 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced interim data from an ongoing, open-label, pilot Phase 2 study of XmAb®5871 in patients with active IgG4-Related Disease (IgG4-RD). The data were presented today by John H. Stone, M.D., MPH, director of rheumatology at Massachusetts General Hospital, at the Annual European Congress of Rheumatology (EULAR 2017). "We continue to be very encouraged by the rapid initial response in IgG4-RD disease activity observed in this interim data set, in which now 14 of 15 patients evaluated for IgG4-RD Responder Index (RI) achieved a response, with initial responses typically occurring after the first dose and deepening over time," said Paul Foster, M.D., chief medical officer of Xencor.

  • Capital Cubelast month

    ETFs with exposure to Xencor, Inc. : June 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Xencor, Inc. Here are 5 ETFs with the largest exposure to XNCR-US. Comparing the performance and risk of Xencor, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)